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In this review, the development of organocatalytic artificial enzymes will be discussed. This area of protein
engineering research has underlying importance, as it enhances the biocompatibility of organocatalysis for
applications in chemical and synthetic biology research whilst expanding the catalytic repertoire of
enzymes. The approaches towards the preparation of organocatalytic artificial enzymes, techniques used
to improve their performance (selectivity and reactivity) as well as examples of their applications are
presented. Challenges and opportunities are also discussed.Introduction
Biocompatible organocatalysis
Serving as a major tool for asymmetric chemical trans-
formations,1–3 organocatalysis has now matured to a point
where its bio-orthogonality can be exploited for important
chemical and synthetic biology applications. Catalysts such as
imidazolidinone,4–6 proline,7 thiourea,8 and anion–p9 deriva-
tives have been used to mediate reactions that have no parallel
in nature. Provided its bio-orthogonality, organocatalysis can be
used in biological contexts for valuable chemical and biological
applications.10–17 For instance, organocatalysts can serve to
mediate labelling of biomolecules,11,12 analogous to existing
approaches that use metals for reactions.18–20 Also, it is worthlexander R. No¨dling is a Post-
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f Chemistry 2020considering to merge organocatalysis and biocatalysis for the
production of chiral synthons in a one-pot and atom economic
fashion.13–17 However, there are only a few examples where
organocatalysts function along with biomolecules or under
biological conditions. In fact, taking into account the aqueous
reaction medium, physiological pH (near 7.4) and temperature
(near 37 C),20 many of the reported organocatalysts do not
function under biocompatible conditions.8,10,17,21–31 These
boundaries vastly narrow the number of organocatalytic reac-
tions applicable and, in response, efforts have been made to
overcome limitations related to biocompatibility.17,32,33
The use of proteins to host organocatalysts
To enhance the biocompatibility of organocatalysis, biomole-
cules including DNA, RNA and proteins can be used to host the
reactions.34–44 Among them, proteins are particularly suitable.
Most proteins can be made recombinantly, correctly folded inNicolo` Santi was born in
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View Article Onlinean aqueous environment under physiological conditions and
are thus inherently biocompatible. Yet, the outer surfaces and
interior of most proteins possess relatively low dielectric
constants, which are similar to those found in many organic
solvents.45 Consequently, proteins can provide a microenviron-
ment that can stabilise the transition state during chemical
transformation.34,46,47 Furthermore, superior to most organic
solvents, proteins are inherently chiral – the scaffold where the
catalytic motif is located can be modelled and/or genetically
modied for improved selectivity.48 Most importantly, the
protein host can be further rened by laboratory evolution,
which has become increasingly facile as molecular cloning and
screening techniques have become user-friendly.49,50 In
contrast, it is relatively difficult to incorporate such “evolv-
ability” in traditional catalyst design.34,36,48,49,51–54 To this end,
the creation of genetically encoded protein scaffolds is a prom-
ising avenue to develop biocompatible stereoselective organo-
catalytic reactions.36,55Thomas L. Williams graduated
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16148 | RSC Adv., 2020, 10, 16147–16161Articial organocatalytic enzymes
The term “articial enzyme” has been widely used for any
macromolecular complex designed to catalyse chemical reac-
tions.54 Herein, we describe articial enzymes as protein-based
systems that have been genetically or chemically altered,
repurposed or designed de novo to catalyse a reaction. While
contemporary articial enzyme design is mainly focused on
metallo-enzymes or redesign of reaction-promiscuous natural
enzymes,49,56 we set the scope of this review to the development
of articial organocatalytic enzymes based on recombinant
proteins. These enzymes were categorised based on their design
(Table 1). We will describe relevant examples of each strategy
and the success in their approach. Engineering of natural
cofactors in their native enzymes will be briey discussed.17,32Chemical modification
Site-selective chemical modication of proteins
Prior to the onset of modern molecular biology technologies,
proteins were oen chemically modied to purposefully alter
their activity.77–79 Initially, modied enzymes were made by
single atom replacement. Serine protease subtilisin was con-
verted to its cysteine equivalent by a three-step chemical
protocol (tosylation, followed by replacement with thioacetate
and hydrolysis).80 The resulting “thiol-subtilisin” could hydro-
lyse activated aryl substituted ester bonds. However, this
cysteine variant lost its protease activity and was found to be
100-fold less active than the parental enzyme towards activated
esters, despite the higher nucleophilicity of the free thiol.81,82 In
another study, selenosubtilisin was created by converting the
active site serine residue into selenocysteine.57,58,83 The
selenium-containing protein was shown to be a reductase; alkyl
peroxides could be converted to their alcohol equivalents under
the action of this modied enzyme using thiophenol as a source
of oxidant (Fig. 1a).57 The articial enzyme exhibits reaction
rates comparable to those of natural enzymes. WhileLouis YP Luk is a Lecturer at the
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Table 1 Advantages and disadvantages of the five approaches used for performing organocatalysis in a protein scaffold
Systems Features Advantages Potential challenges Reactions tested
Site-selective modication
with catalytically active
motifs
Relative ease of
preparation; quick
screening of different
catalytic moieties possible
Site-specic labelling can
be challenging
Reduction;57,58
cyclisation;59 reductive
amination;60 C–C bond
formation61
Computational design of
active site, creating
“theozyme”
High probability to create
a novel active site as
a consequence of precise
design, and hence
screening time is
minimised
Mechanistic and structural
knowledge needed;
knowledge in
computational chemistry
needed
(Retro-)aldol reaction;62–68
Henry reaction;41
Knoevenagel
condensation;24,43
conjugate addition40,42,44
Use of substrate
promiscuous N-terminal
proline
No need of chemical
modication or computer
modelling
Limited to secondary
amine organocatalysis at
the N-terminal position; is
it very easy to generate
protein with N-terminal
Pro recombinantly
Conjugate addition;38,69–71
intramolecular and
intermolecular aldol
condensation37,72,73
Genetic incorporation of an
unnatural amino acid
which bears (part of the)
catalytically active motif
Wide selection of
catalytically active amino
acids; no chemical protein
modication needed
Recombinant expression
might be low yielding
Ester hydrolysis;74 oxime/
hydrazone conjugation50,75
Binding of a ligand bearing
catalytically active motifs
Many catalytically active
moieties can be attached;
enable quick screening of
different catalytic moieties
Limited to proteins with
high affinity ligand(s)
Conjugate addition;39
decarboxylative Michael
addition;36,55 domino
aldol–Michael reaction76
Fig. 1 Selenosubtilisin catalyses the reduction of (a) tert-butyl
hydroperoxide and (b) secondary alkyl hydroperoxide. MES ¼ 2-(N-
morpholino)ethanesulfonic acid, EDTA ¼ ethylenediaminetetraacetic
acid.
This journal is © The Royal Society of Chemistry 2020
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View Article Onlinemechanistic insights are not available, the selenosubtilisin
displays an inverted enantioselectivity in the kinetic resolution
of racemic peroxides when compared to the native enzymes
(Fig. 1b).58
Cysteine, due to its nucleophilic nature, is most frequently
modied with cofactors for the creation of new organocatalytic
articial enzymes. An articial oxidoreductase was created by
linking the catalytically active cysteine residue of the protease
papain to avins. Using oxygen for oxidation, the resulting
“avopapain” was able to oxidise NADH and its derivatives at
a rate 50-fold higher than that by avin alone (Fig. 2a).84 Simi-
larly, the natural cofactor thiamine was introduced to papain.RSC Adv., 2020, 10, 16147–16161 | 16149
Fig. 2 Artificial enzymes created by covalent modification of cofac-
tors: (a) artificial flavopapain used for the oxidation of BNAH; (b) arti-
ficial thiazolopapains for C–C bond formation; and (c) artificial ALBP–
pyridoxamine for enantioselective reductive amination. Tris ¼ tris(hy-
droxymethyl)aminomethane, HEPES ¼ (4-(2-hydroxyethyl)-1-pipera-
zine-ethanesulfonic acid), ALBP ¼ adipocyte lipid binding protein.
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View Article OnlineThe resulting “thiazolopapain” was one of the early articial
enzymes that can mediate C–C bond formation.59 Nevertheless,
activity was suboptimal, as the model cyclisation reaction of 6-
oxo heptanal required six days to reach completion with
a signicant portion of substrate transformed in dimerisation
byproduct (Fig. 2b). A third cofactor, pyridoxamine, was used to
label the adipocyte lipid binding protein.60 The pyridoxamine
protein complex could successfully mediate the production of
a wide range of amino acids with modest to excellent enantio-
selectivity with enantiomeric excess (ee) up to 94% (Fig. 2c).
Recently, an alternative labelling strategy based on the
metabolism of carbapenems by penicillin binding proteins was
developed.61 In this work, secondary amine containing peni-
cillin derivatives were anchored to beta-lactamase and the
covalently modied protein was employed in a conjugate
addition of nitromethane to cinnamaldehyde, giving moderate
yields and low enantioselectivities (20–27%, e.r. z 55 : 45).
These studies lay the foundations for the future development
of protein-hosted organocatalysis.57,84,85 Chemical methodolo-
gies for protein labelling have vastly diversied and improved in
recent years, showing ne-tuned reactivity and biocompatibility
with labelling achieved within live cells.86–94 One can anticipate
that efficient articial enzymes can be made by adapting these
novel technologies.Fig. 3 Net reaction of methodol (1) cleavage catalysed by the de novo
designed retro-aldolases and important intermediates.De novo design/laboratory evolution
Development of de novo enzymes
The increase in computational power and applicable soware,
including Rosetta and ORBIT,95 has accelerated the16150 | RSC Adv., 2020, 10, 16147–16161development of de novo enzyme design.96,97 The rst stage of de
novo enzyme design is the in silico generation of a “theozyme,”
a theoretical arrangement of side chain residues and bioavail-
able molecules (water and ions) that can stabilise the rate-
limiting transition state(s) of a chosen reaction.98 This
assembly of theozyme is subsequently transformed into an
experimentally tangible protein structure through evaluations
based on calculated parameters (e.g. geometry and energy) by
screening of available protein structures available in reposito-
ries.49,95 Eventually, the best options are recombinantly
produced for characterisations. The initial de novo enzymes are
typically inefficient and are not selective. Thus, laboratory
evolution is used to enhance both catalytic activity and reaction
prole. This pathway led to the formation of a highly competent
and promiscuous de novo Kemp eliminase,99,100 retro-aldolases
(RA)40,43,44,63,65–68 and Diels–Alderases.52,101 Here, we will focus
on retro-aldolases which bear a catalytically active lysine for
iminium and enamine catalysis.
Retro-aldolases are a class of de novo designed enzymes
capable of catalysing retro-aldol reactions via formation of an
iminium intermediate.68 Retro-aldolases have been created
from a theozyme that is able to mediate cleavage of the uo-
rogenic compound methodol (1, Fig. 3).68 The reaction was
selected to allow for facile screening as the retro-aldol product
naphtaldehyde (2) is uorescent.
Themost effective theozyme in terms of rate enhancement in
the recombinantly produced protein contains a catalytically
active lysine residue within a hydrophobic binding pocket and
a strategically positioned water molecule that helps mediating
formation of the Schiff base intermediate.68 Interestingly, this
articially designed network was found to be catalytically more
active than those made based on naturally found proton shuffle
networks. Computational tools, such as RosettaMatch,96 were
recruited to dock the theozyme into a protein scaffold, creating
a suitable host for the articial active site.
Indole-3-glycerol phosphate synthase,102 a TIM-barrel
protein fold, was identied for hosting the theozyme. Further
adjustment of the residues surrounding the transition state was
made using RosettaDesign, which among other purposes
enables optimisation of residue interactions around the active
site.103 Among these active models, the variant RA95.0 with the
catalytically active lysine at position 210 (apparent pKa ¼ 8.1,
Fig. 4) was identied as the most promising candidate. Exper-
imentally, RA95.0 is able to mediate cleavage of methodol (1)This journal is © The Royal Society of Chemistry 2020
Fig. 4 Overlay of crystal structures of the first retro-aldolase RA95.0
(gold & orange, PDB: 4A29), in which Lys210 is responsible for forming
the Schiff base intermediate with a 1,3-diketone inhibitor and the
evolved variant RA95.5-8 (light & dark blue, PDB: 5AN7) that carries
a novel catalytically active Lys83 (in complex with a 1,3-diketone
inhibitor).
Fig. 5 Promiscuity of RA95.5-8 and variants for carbon–carbon bond
forming reactions. Iminium catalysis includes: (a) conjugate addition of
carbon nucleophiles; (b) conjugate addition of nitromethane; (c)
Knoevenagel condensations of carbon nucleophiles with a,b-unsat-
urated aromatic aldehydes and (d) Henry addition of nitromethane to
aromatic aldehydes. Enamine catalysis includes: (e) conjugate addition
Review RSC Advances
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View Article Onlinewith catalytic efficiency (kcat/KM) of 0.19 M1 s1 and selec-
tivity for S over R (2.3 : 1).66,67 To create an enzyme with
improved performance, regions at and around the active site of
RA95.0 were subjected to iterative cassette mutagenesis, a form
of saturation mutagenesis where pre-synthesised and mutated
DNA strands are inserted into the gene by restriction enzyme
digest and ligation.104 By combining mutations of the most
active single variants, a highly improved variant RA95.5, which
has six mutations in total, showed 73-fold increase in catalytic
efficiency when compared to RA95.0 (kcat/KM ¼ 14 M1 s1 with
3 : 1 R-to-S selectivity). Crystallographic studies revealed that
the T83K mutation in RA95.5 created a second reaction centre,
in addition to Lys210, both capable of forming Schiff base
intermediates. This nding indicated that the active site
underwent restructuring, and further renement was needed
(see below).66,67 In particular, the replacement of T83K mutation
shied the pKa of Lys210 to 7.6, to which the authors attributed
the improved performance.
Additional laboratory evolution studies of the entire gene
(error-prone PCR and DNA shuffling) created the variant
RA95.5-5 that has an additional six mutations (compared to
RA95.5) and demonstrated signicantly improved activity
(>20-fold, kcat/KM ¼ 320 M1 s1, and selectivity 5 : 1 R over S).
Crystallographic studies illustrated that Lys83 transformed
into the only reaction centre for the methodol (1) cleavage,
indicating that there is a switch in location of the residue
responsible for catalysis.66 Restructuring of the active site was
likely unpredictable during the initial design, highlighting
that randomness is a key element during the evolution of an
efficient enzyme. Finally, a last three rounds of laboratory
evolution yielded the variant RA95.5-8 (Fig. 4), which contains
substitutions at both the active site and distal positions, and
its catalytic efficiency (kcat/KM) was measured to be 850 M
1
s1.66This journal is © The Royal Society of Chemistry 2020Aldolase evolution
Showcasing the power of ultra-high throughput screening
methods, microuidic uorescence-activated droplet sorters
(FADS) were used to further improve the performance of the
retro-aldolase. The resulting variant RA95.5-8F displayed 13
mutations and a 30-fold higher activity (kcat/KM ¼ 34 000 M1
s1 for (R)-methodol (R-1) with 480 : 1 R over S selectivity).64
Such impressive improvement was attributed to the genesis of
a catalytic Lys-Tyr-Asn-Tyr tetrad for proton shuffling. The
tetrad forms a hydrogen bonding network which transfers
proton to and from the reaction centre, stabilising formation of
reaction transition states. RA95.5-8F was the rst RA to be able
to mediate aldol reactions between acetone and various alde-
hydes (i.e. an aldolase). It should be noted that previous RA's
were inhibited by the formation of Schiff base with these alde-
hydes, whereas RA95.5-8F selectively forms enamines with
acetone.Expanding the reaction prole of the RA95 family
A series of studies were conducted to expand the versatility of
the RA95 family to catalyse different reactions (Fig. 5). Iminium
catalysis mediated by RA95.5-8 was used as a means to mediate
carbon–carbon bond formation, including conjugate additions
(Fig. 5a and b),40,42,44 Knoevenagel (Fig. 5c)43 and Henryof acetone to nitrostyrene.
RSC Adv., 2020, 10, 16147–16161 | 16151
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View Article Onlinecondensations (Fig. 5d).41 Enamine catalysis was also explored
in the nitro-Michael addition of acetone to nitrostyrenes
(Fig. 5e).42 In some cases, formation of reactive iminium species
was veried by reduction of the intermediates followed by mass
spectrometric analysis.43,44
During the course of optimising RA95.5 to mediate different
transformation (Fig. 5), several notes have been learned. Firstly,
there is a positive correlation between stereoselectivity and
catalytic efficiency.63–68 Nevertheless, it should be noted that,
during the optimisation process, stereoselectivity may be weak
because the active site undergoes reconstruction (e.g. re-
locating the catalytic residue);40,41,44 eventually, stereo-
selectivity resumes and variants with kinetic parameters and
selectivity similar to those of natural enzymes can be achieved.
Furthermore, rened articial enzymes oen possess properties
similar to those of natural enzymes. For instance, loop exibility
and residues that are distant from the active site (secondary
shell and protein surface) could greatly affect the performance
of the catalysis.41,42,44,105,106 In another instance, it was indicated
that catalysis is partially driven by a negative activation heat
capacity, which is considered as a result of tight binding to the
transition state forming an ordered complex.62 Finally, the
computationally designed 248-residued RA can be modied at
approximately 30 positions. This signies the genetic “plas-
ticity”107,108 of RA and echoes the fact that TIM-barrel fold is
found in at least 15 families of enzymes.109–111 The coupling of
computational design (rational) and laboratory evolution with
high-throughput screening (randomness) has proven to be an
effective approach to create de novo enzyme. In recent years, this
technology has been combined with others, including genetic
code expansion (see below). We anticipate that the family of de
novo enzymes will soon be vastly expanded.N-Terminal proline
4-Oxalocrotonate tautomerase
When located at the N-terminus of a protein, proline offers
a secondary amine that can be used for iminium- and enamine-
based organocatalysis. One such example is 4-oxalocrotonate
tautomerase (4-OT) from M. putida, which is composed of sixFig. 6 (a) Hexameric crystal structure of 4-OT (PDB: 4X19), monomer
subunit highlighted in dark blue. (b) Native reaction of 4-OT, showing
the net reaction in the upper part and the function of the N-terminal
proline as general base below.
16152 | RSC Adv., 2020, 10, 16147–16161homologous monomers carrying a catalytic N-terminal proline
(Fig. 6a).112 Naturally, this residue acts as a general base, cata-
lysing the tautomerisation of a dienol into an unsaturated
ketone (Fig. 6b).38,113,114 Interestingly, this proline residue forms
iminium intermediates with various carbonyl substrates.
Because of its signicant substrate promiscuity, 4-OT has
been used as an organocatalyst for chemical transformations. It
has been demonstrated that 4-OT is able to catalyse enamine-
based aldol reactions (Fig. 7a and b)37,70 and conjugate addi-
tions (Fig. 7c).71 Additionally, 4-OT has been exploited for imi-
nium catalysis, including the conjugate addition of
nitromethane (Fig. 7d).115 Reduction of the intermediate imi-
nium ion by sodium cyanoborohydride and subsequent mass
spectrometry analysis provide evidence that supports the
formation of the iminium intermediate.73
Mutagenesis via a combined computational and experi-
mental approach has led to the identication of enhanced
variants. Three residues in proximity were found to be crucial
for catalysis, including Phe50, Met45 and Ala33. Mutability
landscapes were used to determine ‘residue hotspots.’ The
experiment consisted of singly mutating all amino acids with
the exception of the catalytic Pro1.
Protein solubility of single point mutations was rst
assessed, followed by an activity screen of the tautomerization
reaction and subsequently the Michael addition. An F50A
mutation resulted in an increase of catalytic efficiency by
a factor of 600 for cross-coupling aldol reactions.72 In contrast,
when both Phe50 and Met45 were replaced with valine and
tyrosine respectively, the resulting variant was more effective at
self-condensation reactions. The F50V/M45Y double mutant
resulted predominantly in the R product, whereas a third
mutant A33D selectively yielded the S enantiomer in the
conjugate additions of acetaldehyde to b-nitrostyrenes.69 CrystalFig. 7 Reactions catalysed by 4-OT include (a) intermolecular aldol;
(b) intramolecular aldol; (c) nitro-Michael addition; and (d) enamine
catalysed conjugate addition. 4-OT ¼ 4-oxalocrotonate tautomerase.
This journal is © The Royal Society of Chemistry 2020
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View Article Onlinestructures of the two mutants have been obtained, but the N-
terminal region was not resolved likely due to its inherent
exibility. Hence, the actual assembly in the active site remains
unclear.
4-OT and its variants have been used for a range of appli-
cations including enzymatic115 and chemoenzymatic
cascades,116 alongside whole cell catalytic systems.117–119 The
anti-anxiety drug pregabalin and three of its analogues were
synthesised by coupling the 4-OT reaction with catalysis by
aldehyde dehydrogenase (ALDH, Fig. 8).
Acetaldehyde was added stereoselectively to a,b-unsaturated
nitro substrates under the action of a 4-OT variant, followed by
oxidation by ALDH to yield the corresponding carboxylic acid
(Fig. 8).116 To recycle NADH, a cofactor recycling system oper-
ated by NAD oxidase (NOX) was included. Lastly, the nitro group
was reduced to the amine using sodium borohydride in the
presence of nickel chloride. These applications present
evidence that protein-based organocatalysis can be used in
combined synthesis which may not be readily achievable using
traditional organocatalytic systems.
Utilising only natural residues with no chemical modica-
tion needed, the N-terminal proline approach is arguably the
simplest in establishing a biocompatible organocatalytic
system. As a range of reactions have already been established, 4-
OT is an attractive system for performing organic reactions in
biological contexts. However, a major limitation is that it is only
able to catalyse secondary amine organocatalysis. Other useful
organocatalytic transformations (based on e.g. thiourea or
counterion based catalysis) are unavailable and thus other
approaches must be employed.Genetic code expansion
Fundamentals of genetic code expansion
Genetic code expansion enables site-specic incorporation of
unnatural amino acids, which can be used to mediate bio-
orthogonal chemical reactions. To achieve this goal, a pair of
orthogonal aminoacyl-tRNA synthetase/tRNA pair is needed.
Specically, the orthogonal tRNA decodes a blank codon,Fig. 8 Chemoenzymatic synthesis of pregabalin and three of its
analogues using 4-OT. NAD ¼ nicotinamide adenine dinucleotide,
ALDH ¼ aldehyde dehydrogenase, NOX ¼ NADH oxidase.
This journal is © The Royal Society of Chemistry 2020commonly the amber stop codon (TAG) as it is oen the least
used codons in most organisms. To produce recombinant
proteins that contain unnatural amino acids in E. coli,
pyrrolysyl-tRNA synthetase/tRNA and tyrosyl-tRNA synthetase/
tRNA pairs from archaea are the most versatile and popular
choices.120 The pyrrolysyl-tRNA synthetase/tRNA pair is partic-
ularly useful as it naturally decodes the amber codon.121 To
incorporate the unnatural amino acid, a TAG codon is then
introduced into the gene of interest at the position of choice.
Double transformation of E. coli with plasmids containing the
gene of interest and the synthetase are conducted. By including
the unnatural amino acid in the medium, the orthogonal
synthetase specically charges the orthogonal tRNA with the
unnatural amino acid, which will allow for production of full-
length protein with the unnatural amino acid at the desired
position. To date, over 200 unnatural amino acids can be
genetically incorporated into a protein of interest using this
technique, so there exists a vast opportunity to exploit these
unnatural amino acids for organocatalytic transformations
(Fig. 9).91The multidrug regulator protein LmrR
LmrR is a dimeric protein isolated from Lactococcus lactis that
has a hydrophobic pore in the centre, allowing for theFig. 9 Incorporation of unnatural amino acids by genetic code
expansion in E. coli. (a) Double transformation of two plasmids, in
which one bears an exogenous amino acid tRNA synthetase (RS) and
cognate tRNA, whereas the other contains the gene of interest (GOI)
with a site-specific TAG mutation. (b) Expression of the tRNA synthe-
tase and addition of the unnatural amino acid (UAA) allows the tRNA to
be charged with the UAA. (c) Ribosomal translation of the GOI with the
unnatural amino acid incorporated site specifically into the protein.
ATP ¼ adenosine triphosphate, PPi ¼ inorganic pyrophosphate.
RSC Adv., 2020, 10, 16147–16161 | 16153
Fig. 10 (a) Crystal structure of the homodimeric protein LmrR (PDB:
3F8F). Residues in red are those targeted for unnatural amino acid
incorporation (Asn19, Met89, Phe93). Residues in blue (Val15) show the
most promising result, when they are replaced with the unnatural
amino acid p-amino-phenylalanine. (b) Hydrazone and oxime ligation
performed by the unnatural amino acid. (c) Conjugate addition cata-
lysed by dual substrate activation using LmrR V15pAF and a copper
complex. (d) Postulatedmechanism for the conjugate addition via dual
activation from (c). (d) Adapted from ref. 122, https://
www.nature.com/articles/s41929-019-0420-6, with permission of
Springer Nature, copyright 2020. Further permissions related to the
material excerpted should be directed to Springer Nature. DMF ¼
dimethylformamide, phen ¼ phenanthroline, pAF ¼ p-
aminophenylalanine.
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View Article Onlinerecruitment of organic molecules (Fig. 10a). Four positions
located within the hydrophobic pore (Val15, Asn19, Met89 and
Phe93) were individually mutated to a TAG codon and tested for
the incorporation of the unnatural amino acid p-azidopheny-
lalanine under the action of an evolved tyrosyl-tRNA synthetase
fromMethanococcus jannaschii. The azido group was chosen and
subsequently reduced to the catalytically active aniline, because16154 | RSC Adv., 2020, 10, 16147–16161direct incorporation of p-aminophenylalanine proved to be
challenging.75 The designer enzyme was then tested for hydra-
zone and oxime formation. It was found that unnatural amino
acid replacement at the Val15 position yielded the most prom-
ising result (Fig. 10b).75 Laboratory evolution was used to screen
the library variants in 96 well plates by measuring the loss of the
UV absorbance from the substrate.50 The resulting variant
which carries additional mutations, including A11L, N19M,
A92R and F93H, showed a 74-fold increase in catalytic effi-
ciency. Based on the knowledge of these positions from
previous structures, Leu11 and Met19 are thought to help
position the aniline in a more “reaction-ready” position.
Furthermore, Arg92 was reasoned to stabilise the build-up of
negative charge that appears during the condensation of the
aniline with the carbonyl group. Lastly, His93 was proposed to
serve as proton shuttle assisting in the formation of iminium
ion intermediates and promoting the transamination
processes.
Recently, the p-aminophenylalanine/LmrR system has been
further modied for a novel dual substrate activation strategy.122
Through combination with a supramolecularly bound Lewis
acidic Cu(II) complex, the resulting articial enzyme was able to
mediate a Michael reaction that involves both formation of
a Cu-enolate and an organocatalytic iminium intermediate.
Yields of this novel reaction mode were up to 90%, with d.r. and
ee up to 9 : 1 and >99% respectively. This work highlights that
importance of developing different approaches to articial
enzyme design (e.g. genetic code expansion and supramolecular
approach), as proteins can be used to host multiple catalytic
centres for coupled reaction cascades.De novo designed BH32
BH32 is an enzyme originally created by Rosetta to perform the
Morita–Baylis–Hillman reaction,101 and this protein has been
further re-engineered into a potent hydrolase through the
combined use of genetic code expansion and laboratory
evolution.74 Substitution of the catalytic His23 with methyl-
histidine was achieved by using an evolved variant of the
pyrrolysyl-tRNA synthetase and its cognate tRNA (Fig. 11a).
The resulting enzyme was able to perform ester hydrolysis for
a range of compounds that uoresce upon reaction (Fig. 11b).
Screening for variants with improved activity was performed
using 96 well plates on a plate reader where formation of the
uorescein product could be monitored. Six mutations resul-
ted in a 15-fold increase in enzyme activity. Mutations result-
ing from the evolution were L10P, A19H, S22M, E46N, P63G
and D125G. Based on the data derived from crystallography
and kinetic investigations, the authors concluded that the
aromatic ester formed between the substrate and Me-His was
signicantly more prone to hydrolysis (Fig. 11c). In contrast,
the neutral acyl enzyme intermediate formed from the natural
amino acid histidine hydrolyses slowly under the same
condition.
The technique of genetic code expansion allows exploration
beyond the limit of what natural amino acids offer, thus holding
great promise in contemporary enzymology. Incorporation ofThis journal is © The Royal Society of Chemistry 2020
Fig. 11 (a) Crystal structure of the protein BH32 (PDB: 6Q7N). Residue
in blue is the unnatural amino acid methyl-histidine bound to aceto-
phenone (red). (b) Substrate scope of the ester hydrolysis performed
by BH32 with the unnatural amino acid Me-His. (c) Shortened mech-
anism of the acyl enzyme intermediate formation of BH32 Me-His23
with aromatic esters. PBS ¼ phosphate-buffered saline, DMSO ¼
dimethyl sulfoxide.
Fig. 12 Combination of a catalytically inactive protein scaffold with
a ligand–catalyst conjugate leads to a catalytically active supra-
molecularly assembled protein complex.
Review RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
3 
A
pr
il 
20
20
. D
ow
nl
oa
de
d 
on
 4
/2
3/
20
20
 1
:5
7:
42
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineunnatural amino acids in vivo enables laboratory evolution in
a fashion similar to those of natural enzymes. Consequently,
articial enzymes made by this fashion can also be applied to
whole cell catalysis or synthetic biological pathways. However,
the efficiency of incorporation greatly depends on the unnatural
amino acid used. The choice of protein to harbour the amino
acid also needs to be considered carefully. Both LmrR and BH32
have been previously used in articial enzyme design (LmrR for
articial metallo-enzymes and BH32 was computationally
designed for carbon–carbon bond forming reactions).47,92 Both
examples have shown promise in performing biocompatible
organocatalysis. As genetic code expansion has become moreThis journal is © The Royal Society of Chemistry 2020readily available, this technique will likely gain increasing
popularity in the future of enzyme design.Non-covalent supramolecular systems
Harnessing non-covalent interactions
Non-covalent but strong protein–ligand interactions have been
exploited to generate organocatalytic articial enzymes. In these
systems, a catalytic moiety is covalently attached to a section of
a ligand that is only weakly involved in protein binding and
introduced to the protein partner. Consequently, the resulting
protein–ligand complex is converted into a potential catalytic
entity (Fig. 12).
When compared to other approaches, a supramolecular
complex has little restrictions on the choice of the catalytic
motifs. Preparation of the modied ligands tends to be
straightforward, involving simple synthetic techniques such as
amide bond coupling and click chemistry.35,39,123–126 Hence, the
supramolecular approach enables researchers to screen activity
for a broad range of candidates within a short period of time. In
addition, the protein hosts can still be engineered via rational
design or laboratory evolution.46,48,127–129 To this end, the
supramolecular approach is an important technique for
creating articial enzymes. As a rule of thumb, the supramo-
lecular catalytic complexes are built based on protein–ligand
interactions that have dissociation constants (KD) ranging from
low mM to pM.123–125,130
The ligand needs to possess a site for easy functionalisation
while causing minimal effect on protein–ligand interaction.
One such pair is the (strept)avidin and biotin, whose KD value is
approximately 1014 M1.130 The (strept)avidin–biotin system
has already been exploited in the late 1970s to tether a rhodium
catalyst to the valeric motif of biotin for asymmetric hydroge-
nations.131 Subsequently, a variety of streptavidin based arti-
cial metallo-enzymes operated by iridium, rhodium, ruthenium
and palladium have been reported.35,48,123,126,127,132,133 Below we
describe two different types of organocatalytic articial enzymes
based on biotin–streptavidin.
Anion–p-catalysis has become a contemporary topic in
organocatalysis.9,134–139 In this catalytic mode, anion intermedi-
ates formed during the reaction can be stabilised by p-acidic
molecules such as naphthalenediimides (NDIs, bold blue core
in 11, Fig. 13a), which possess a positive quadrupole moment.
This consequently facilitates organic transformations such as
conjugate additions (Fig. 13b). Whereas all natural aromatic
amino acids are p-basic and interact with cations, theRSC Adv., 2020, 10, 16147–16161 | 16155
Fig. 13 (a) Reported biotin–NDI–amine organocatalyst conjugates,
NDI fragment in bold and blue.36 (b) Decarboxylative Michael addition
reaction catalysed by 14 within S112Y mutant streptavidin. Sav ¼
streptavidin.
Fig. 14 (a) Cartoon overview of the assembly of streptavidin with full
binding-site occupation with D-biotin in both binding sites, mono-
meric unit in light blue. The C2 symmetric interface of two streptavidin
subunits is illustrated (PDB: 1MK5). Amino acids Ser112, Lys121, and
Leu124 are highlighted. Purple loop regions represent amino acids
46–52. The other two subunits of the homotetrameric streptavidin are
omitted for illustration purpose. (b) Cartoon overview of a single
binding-site of anion–p catalyst 14 in Sav S112Y. (b) Adapted from ref.
36, https://pubs.acs.org/doi/abs/10.1021/acscentsci.6b00097, with
permission of ACS, copyright 2016. Further permissions related to the
material excerpted should be directed to the ACS.
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View Article Onlinestreptavidin–biotin technology was recently used to create an
organocatalytic articial enzyme that drives catalysis by anion–
p interactions.36,76
To add anion–p interactions into the repertoire of enzyme
catalysis, a combined chemical and genetic screening approach
was used. A library of ve bifunctional catalytic moieties were
attached to biotin (compounds 11–15, Fig. 13a) that contain
both an NDI motif and a tertiary amine connected through
a linker of different length. The p-acidic surface of the NDI
motif was proposed to be able stabilise the enolate intermediate
formed in the reaction, whereas the tertiary amine acts as a base
and localises the enolate intermediate over the NDI moiety.140
Hence, their ability to mediate a decarboxylative alkylation
between thioester malonates and nitrostyrenes was evaluated
(Fig. 13b).36
Ligand 14 was identied to be most reactive, and the activity
was screened using a streptavidin library of 20 variants. The
combination of ligand 14 and S112Y variant yields an organo-
catalytic articial enzyme that selects for product formation
over the decarboxylated starting material at a ratio >30 : 1. The
conversion in ACN : glycine buffer at pH 3.0 was found to be
90% with e.r. up to 97.5 : 2.5.
Based on the site-directed mutagenesis studies and docking
simulations, a plausible mechanism operated by ligand 14/Sav-
S112Y was proposed. A medium sized linker between biotin and
NDI (i.e. ligand 14) is essential to accommodate the catalytic
unit close to the biotin-binding vestibule, whilst not causing any
steric clash. Large electron-withdrawing substituents at the NDI
motif were found to weaken the binding (13 vs. 14, Fig. 13a),
while a exible dimethylene bridge instead of a rigid one (12 vs.
14, Fig. 13a) hampers both the conversion and selectivity. The
tertiary amine/NDI motif locates in close proximity to the16156 | RSC Adv., 2020, 10, 16147–16161intersubunit interface of the homotetrameric streptavidin,
which has a C2 symmetry (Fig. 14a). Hence, residues from both
monomers can interact with the catalyst and substrates,141 and
the docking studies revealed that the S112Ymutation from each
monomer, namely S112YA and S112YB, is essential to the
catalysis by ligand 14.
When the ligand is bound to monomer A, the NDI motif
forms p–p-interactions with S112YA; this is supported by the
observation that the mutant S112E and S112W resulted in
decreased activity, while the S112F mutant showed similar
reactivity to that of S112Y (Fig. 14b). In contrast, S112YB shiel-
ded its own biotin binding site. Accordingly, optimal activity
was obtained when the catalyst to free binding-sites ratio was
kept at 1 : 2. The wild type lysine residues Lys121A and Lys121B
anchor the NDI at the designated location. Furthermore,
Lys121A helped maintaining a low pKa value for the tertiary
amine of 14, keeping it in its deprotonated form for reactionThis journal is © The Royal Society of Chemistry 2020
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View Article Online(even at pH 3.0). Mutation of Lys121 led to a detrimental effect
on the activity and selectivity. This study revealed the intricate
interactions between the residues and catalytic motif, thereby
highlighting that screening of both ligands and variants is
critical to obtain an efficient and selective supramolecular
system.
The hybrid catalyst system of streptavidin and conjugate 14
was further employed to perform a bioorthogonal domino-
Michael–aldol reactions between diketones and nitrostyrenes
(Fig. 15).76 With 1–5 mol% catalyst loading, the bicyclic prod-
ucts were obtained in moderate yields (z50%), decent enan-
tioselectivities (0–80% ee) and signicant diastereoselectivity
(>20 : 1) aer screening with four streptavidin mutants. Inter-
estingly, the protein–ligand assembly lead to an inversion of
stereoselectivity when compared to the nascent biotin-catalyst
conjugate.
The biotin-binding-sites in wild-type Sav are rather shallow,
exposing a good portion of the catalytic moiety to the solvent.
The lack of amino acid side chains in proximity makes muta-
tional optimisation difficult to achieve (Fig. 14b). This led to the
development of chimeric Sav variants, which contain insertions
of amino acid loops around the biotin-binding sites of Sav like
naturally occurring random loops or a-helices.55 Eight chimeric
Sav variants containing random coils and alpha helix motifs
inserted between residues 46–52 (purple region, Fig. 14a) and
one with an addition at the C-terminus have been tested as host
for the decarboxylative alkylation catalysed by ligand 14
(Fig. 13b). Though initially thought to increase stereoselectivity
and reactivity, three of these chimeric protein hosts were
completely inactive and the rest showed lower yields and
enantioselectivities than the previously optimised mutant
S112Y. Nonetheless, there are similar levels of selectivity for
product formation over the decarboxylated starting material
(>30 : 1).Fig. 16 (a) Reported biotin–secondary amine organocatalyst conju-
gates.39 (b) Set of Michael addition reactions catalysed by 22 within
a recombinant core streptavidin. (c) Cartoon overview of Sav:(R)-22
crystal structure (green, PDB: 6GH7) and aminol adduct obtained from
QM/MM simulations (golden), and it was adapted from ref. 39, which is
an open access article under the terms of the Creative CommonsSecondary amine organocatalysis
We have recently employed the streptavidin–biotin technology
to create protein-based secondary amine organocatalytic
systems. Seven biotinylated secondary amines (ligands 16–22,
Fig. 16a) were prepared via either copper-catalysed azide–alkyne
cycloaddition or amide bond coupling reactions.39 These cata-
lysts can be broadly segregated into three types: MacMillan-like
imidazolidinones (16–19), prolines (20, 21) and pyrrolidines (22,
23), and their ability to catalyse the Michael addition of nitro-
methane to aromatic a,b-unsaturated aldehydes was tested
(Fig. 16b).
Both (R)- and (S)-22 alone are not enantioselective. However,
when introduced to the tetrameric streptavidin, they were foundFig. 15 Domino-Michael–Aldol-reaction catalysed by 14. Bis-Tris ¼
bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane.
Attribution License, published by Wiley-VCH, copyright 2018, the
authors.
This journal is © The Royal Society of Chemistry 2020to be able to mediate the model reaction with high reactivity
and stereoselectivity.39 Moderate to good yields (37–80%) were
obtained using only 1 mol% of protein catalyst and 1 : 1 MeOH/
potassium phosphate buffer as reaction medium. Notably,
these two protein complexes, namely Sav:(R)-22 and Sav:(S)-22,RSC Adv., 2020, 10, 16147–16161 | 16157
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View Article Onlinediffered by only one chiral centre, but their stereoselectivity was
opposite, with the former favouring for the S enantiomer and
latter for the R enantiomer. Through crystallographic and
computational structural studies, the position of the secondary
amine motif was found to be in proximity to Ser112A. The lysine
and leucine residues located at the dimer interface (Lys121A/B
and Leu124A/B) dictate the face for which the intermediate was
exposed for nucleophilic addition, thereby dictating both regio-
(1,2 vs. 1,4-addition) and enantioselectivity (R and S) of the
reaction (Fig. 16c).39
Based on the precedence of metallo-enzyme development
and supramolecular capsules,142,143 two organocatalytic articial
enzymes that operate distinctively different mechanisms have
been designed. Nevertheless, the conditions developed so far
are not completely biocompatible, as acidic conditions (pH 3.0)
and/or a large volume of organic co-solvents are needed (though
the latter was mostly due to the use of substrate with poor
solubility in aqueous environments).23 Furthermore, activity of
these non-covalent complexes could be potentially optimised
via laboratory evolution, as demonstrated by the existing Sav-
based catalytic systems.46,48,127,128 Though being a robust and
reliable system, issues related to the C2 symmetry of the inter-
subunit interface of Sav was only recently addressed by the
creation of “dimeric” Sav.141 This “dimeric” Sav variant will
facilitate mechanistic studies and the design of tailored and
asymmetric scaffolds for chemical catalysis. In addition to the
streptavidin:biotin system, other protein–ligand systems
should serve as inspiration for novel protein-based organo-
catalytic systems, including the siderophore binding proteins124
or coumarin binding albumins.144
Conclusions and outlook
In this review, we summarised ve approaches which are
currently employed to perform organocatalysis within proteins
(Table 1). The supramolecular tethering and N-terminal proline
approaches have proven to be successful, and chemical catalysis
with improved biocompatibility has been exploited in different
applications including chemo-enzymatic synthesis116 and gene
switches.145 In turn, covalent modication, computational de
novo design and genetic code expansion are anticipated to excel,
as related technologies have vastly improved and gained
popularity in recent years.146–148 Importantly, a much-improved
system can be achieved by combining different approaches.
This can be exemplied by the recent development of LmrR
modied with dual catalytic groups.122 Genetic code expansion
can also be used to introduce novel catalytic functionalities into
a de novo designed enzyme active site. This has been demon-
strated in a recently reported articial metalloenzyme, in which
the designed active site includes the unnatural amino acid
bipyridylalanine for metal binding.149
Despite all these exciting opportunities, there are aspects
that need to be immediately addressed in the area of organo-
catalytic articial enzyme design. Notably, many of the current
systems suffer from poor reactivity, with enzyme loadings up to
20 mol% needed for reaction. However, the development of
RA95, aniline/LmrR and methylated histidine/BH32 have16158 | RSC Adv., 2020, 10, 16147–16161demonstrated that laboratory evolution is a feasible approach
for activity improvement. The choice of protein scaffold and
screening system likely play critical roles during the design.
Furthermore, most protein-based organocatalytic systems are
based on enamine and iminium catalysis that have similar
counterparts in Nature. Useful bioorthogonal reactions that are
frequently used in small molecule synthesis have not been
tested, including a-uorinations, aziridinations and Diels–
Alder reactions.4 Also, sophisticated catalytic modes such as
singly occupied molecular orbital (SOMO)150 activation or
photo-radical chemistry151 can also be explored. In turn, other
useful catalysts, including hydrogen bonding activators (thio-
ureas and squaramides),152,153 N-heterocyclic carbene32,154 and
ion pairing catalysis155 have yet been explored. Additionally,
repurposing avin-dependent enzymes for novel photo-redox
reactions represent a valuable avenue for articial enzyme
design.156–158 In summary, this review illustrated that the design
of articial organocatalytic enzymes has become an exciting
area of research and it will play critical roles in both chemical
and synthetic biology research in future.
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